Form 4: Leap Therapeutics Director Exercises Warrants, Acquires 213 Shares

James Cavanaugh, a director at Leap Therapeutics, exercised warrants to purchase 213 shares of common stock at $2.82 per share.

Summary

• James Cavanaugh, a director of Leap Therapeutics, exercised warrants to purchase 213 shares of the company's common stock.
• The exercise price was $2.82 per share.
• This transaction occurred on November 13, 2024.
• Following the transaction, Mr. Cavanaugh directly owns 213 shares and is also deemed to have indirect beneficial ownership of 261,840 shares held by the HCV VIII Trust.
• Mr. Cavanaugh disclaims beneficial ownership of the shares held by the HCV Trust except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a neutral report of a routine transaction, not indicative of positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies.

Comparison to Industry Standards

• This type of transaction is standard for directors and officers of publicly traded companies.
• The exercise of warrants is a common way for company insiders to acquire shares.
• The reporting requirements are in line with SEC regulations for insider trading.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a small number of shares being acquired by a director.

Key Dates

Keywords

Leap Therapeutics, Director, Warrant Exercise, Beneficial Ownership, Common Stock, SEC Form 4